Article Figures & Data
Figures
- FIGURE 1.
Coronal 18F-FDG PET (A) and AC PET (B) images are shown for patient 14, 77-y-old man with PSA relapse and serum PSA value of 10.5 ng/mL 8 y after radical prostatectomy and 5 y after salvage external-beam radiation therapy. Histologic diagnosis showed Gleason score of 8 at surgery. CT and 111In-capromab pendetide studies were negative for tumor. 18F-FDG PET shows only urinary activity in right ureter (u) and bladder (b). AC PET shows high uptake in multiple paraaortic lymph nodes (n). Incidentally noted is normal uptake in pancreas (panc).
- FIGURE 2.
Coronal images are shown for patient 3, 71-y-old man with PSA relapse and serum PSA value of 3.7 ng/mL 8 y after radical prostatectomy. Histologic diagnosis showed Gleason score of 10 at surgery. (A) 18F-FDG PET is negative for tumor. (B) AC PET shows high uptake in right common iliac lymph node (n) and prostatic bed (pr).
- FIGURE 3.
Coronal and transaxial 18F-FDG PET (A) and AC PET (B) images and CT image (C) are shown for patient 23, 73-y-old man with increasing serum PSA value of 9.1 ng/mL 2 y after external-beam radiation therapy. Histologic diagnosis showed Gleason score of 7 at time of treatment. 18F-FDG PET shows no uptake in prostate and pelvic lymph nodes. AC PET shows bilateral high uptake in iliac lymph nodes (n). CT shows corresponding 1.5 cm iliac nodes (n).
- FIGURE 4.
AC PET results are shown as function of PSA level. Thirteen of 22 patients with serum PSA level > 3 ng/mL had positive AC PET findings, whereas only 1 of 24 patients with serum PSA level ≤ 3 ng/mL had positive findings.
Tables
Patient no. Group Stage* PSA† Gleason score* Age† (y) Positive PET studies Disease confirmation High probability Intermediate probability AC PET 18F-FDG PET AC PET 18F-FDG PET CT Bone scintigraphy Pros biopsy 1 A T1c N0 M0 (pT3) 0.3 7 73 Pros 2 A T2 N0 M0 0.4 7 75 3 A T2 N0 M0 0.4 7 58 4 A T2 N0 M0 0.4 9 60 N N 5 A T2b N0 M0 0.4 9 51 PN 6 A T2 N0 M0 0.5 7 67 7 A T2 N0 M0 0.6 7 63 PN N N 8 A T2 N0 M0 (pT3p N1) 0.6 9 57 N N 9 A T3b N0 M0 (pT3c) 0.6 7 69 10 A T2b N0 M0 0.7 7 59 11 A T2 N0 M0 0.7 Unknown 71 N N 12 A T2b N0 M0 0.8 7 59 N N 13 A T2b N0 M0 0.9 7 73 PN 14 A T2 N0 M0 1.1 7 63 N N 15 A T2 N0 M0 1.2 7 72 16 A T2b N0 M0 1.2 7 57 PN 17 A T2 N0 M0 1.5 7 73 18 A T2 N0 M0 (pT3a) 1.5 7 66 N 19 A T2 N0 M0 1.9 8 68 PN N 20 A T2 N0 M0 2.1 7 66 N 21 A T2b N0 M0 (pT2b N0) 3.5 7 63 N 22 A T2 N0 M0 3.7 10 71 Pros, PN P 23 A T2 N0 M0 3.8 9 69 N N 24 A T2a N0 M0 4.5 7 61 PN 25 A T1c N0 M0 7.9 9 58 B Pros N 26 A T2 N0 M0 (pT3) 9.3 8 60 B B P 27 A T2 N0 M0 (pT3) 10.5 8 77 PAN N N 28 A T2 N0 M0 18.8 79 N 29 A T2 N0 M0 19.2 7 72 PN PN 30 A T2 N0 M0 47.5 7 59 PN, PAN PN, PAN N N 31 B T2 N1 M0 0.5 7 73 32 B T2 N0 M0 1.5 7 73 PN Pros N 33 B T1c Nx M0 2.5 8 61 Pros Pros N N 34 B T2 N1 M0 2.9 7 49 Pros N N 35 B Unknown 3.1 7 58 Pros Pros N 36 B T2 N0 M0 3.4 7 78 PN, PAN PN, PAN 37 B T2a N0 M0 3.5 7 68 38 B T1c N0 M0 5.7 5 72 Pros 39 B T2 N0 M0 6.6 7 55 PN 40 B T2 Nx M0 7.4 6 63 Pros N N P 41 B T1c N0 M0 7.9 5 59 Pros Pros N 42 B T2a N0 M0 8.1 6 63 Pros N N 43 B T1c N0 M0 8.4 6 67 PAN, B Pros P N 44 B T2 N0 M0 9.1 7 73 PN P N 45 B Tx N1 M1 9.9 7 59 PN, PAN, B PN, PAN, B P P 46 B T3c N0 M0 11.5 6 59 Pros N N P Site Number of patients* Group A, postprostatectomy (n = 30) Group B, post-radiation therapy (n = 16) High prob Intermediate prob Total High prob Intermediate prob Total Prostate bed 1 1 2 (7%) 2 8 10 (62%) Pelvic lymph node 4 6 10 (33%) 5 0 5 (31%) Paraaortic lymph node 2 0 2 (7%) 3 0 3 (19%) Bone (metastases) 1 1 2 (7%) 2 0 2 (13%) Overall 6 7 13 (43%) 8 8 14 (88%) ↵* Some patients had more than 1 positive site.
prob = probability.
Site CT Bone scan Prostate (fossa) 0/22 (0%) Not applicable Lymph node 3/22 (14%) Not applicable Bone 0/22 (0%) 2/22 (9%)
In this issue
Jump to section
Related Articles
Cited By...
- Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
- Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities
- Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging
- Anatomic and Molecular Imaging in Prostate Cancer
- Bombesin-Targeted PET of Prostate Cancer
- Evaluation of Prostate Cancer with 11C-Acetate PET/CT
- Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer
- Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
- Dosimetry and First Clinical Evaluation of the New 18F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer
- In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548
- 11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction
- An NMR Metabolomics Approach for the Diagnosis of Leptomeningeal Carcinomatosis
- 11C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation
- Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline
- Functional Imaging of Localized Prostate Cancer Aggressiveness Using 11C-Acetate PET/CT and 1H-MR Spectroscopy
- Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
- Tumor Cell Metabolism Imaging
- Small-Cell Carcinoma of the Prostate
- 1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer
- 1-11C-Acetate Kinetics of Prostate Cancer
- The Role of Indium-111 Radioimmunoscintigraphy in Post-Radical Retropubic Prostatectomy Management of Prostate Cancer Patients
- 18F-Fluoroacetate: A Potential Acetate Analog for Prostate Tumor Imaging--In Vivo Evaluation of 18F-Fluoroacetate Versus 11C-Acetate
- Initial Experience with the Radiotracer Anti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid with PET/CT in Prostate Carcinoma
- 11C-Acetate Positron Emission Tomography Imaging and Image Fusion With Computed Tomography and Magnetic Resonance Imaging in Patients With Recurrent Prostate Cancer
- Parameters for Treatment Decisions for Salvage Radiation Therapy
- 2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy
- microPET and Autoradiographic Imaging of GRP Receptor Expression with 64Cu-DOTA-[Lys3]Bombesin in Human Prostate Adenocarcinoma Xenografts
- Radiation Dose Estimates in Humans for 11C-Acetate Whole-Body PET
- PET Imaging of Prostate Cancer with 11C-Acetate